Long-term changes in skeletal muscle after mixed HIIT training in adults with overweight or obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Thirty adults aged 30-50 with BMI 25-40 kg/m2 who are untrained will be randomly assigned to a 6-month hybrid HIIT program plus a balanced diet or a balanced diet alone. The hybrid program combines cardio and resistance elements in circuit-style sessions three times per week. Researchers will measure anthropometrics, body composition, resting metabolic rate, muscle strength, cardiorespiratory capacity, and collect blood and muscle samples at baseline and after 6 months. The study aims to uncover molecular mechanisms behind long-term benefits of hybrid HIIT on cardiometabolic and musculoskeletal health.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* BMI: \>25 kg/m2 and \<40 kg/m2
* Untrained individuals (abstain \>1 year from exercise training)
* No dietary intervention over the last 6 months preceding the study
* Low cardiorespiratory fitness level (VO2max: \<45 ml/kg/min)
* No use of any medication, dietary supplements
* Low risk for cardiovascular disease
* A weight loss \<10% over the last 6 months preceding the study
* Free of non-communicable diseases (excluding metabolic syndrome)

Exclusion Criteria:

* Low participation rate (\<80% completion of the exercise training sessions)
* Unbalanced diet
* Participation in additional exercise training regimes
* Cosumption of anti-inflammatory of pain relief medication

Where it's running

• Department of Physical Education and Sport Science Trikala, University of Thessaly
  Trikala, Thessaly, Greece Recruiting

Study contacts

• Study coordinator: Ioannis G Fatouros, Professor
• Email: ifatouros@pe.uth.gr
• Phone: 24310 47047

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How incretin treatments affect muscle mass and function in people with overweight or obesity

  This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.

  Recruiting Radboud University Medical Center · Amsterdam and 1 other locations · NCT07929831

• Dose find for remimazolam plus alfentanil for gastroscopy in obese adults

  This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07925684

• Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults

  This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.

  Recruiting Yuzuncu Yil University · Van · NCT07901777

• Gut barrier and inflammation after fast-food overfeeding in adults

  This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.

  Recruiting University Hospital, Gentofte, Copenhagen · Hellerup · NCT07893743

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• GLP-1 weight‑loss medicine: finding who will benefit most

  This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.

  Recruiting Phase 4 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07870538

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.